Human Interest

The U.S. Department of Agriculture just recalled 62,000 pounds of beef due to an E. coli outbreak, creating a nightmare for big grocery chains nationwide.

But for the millions of Americans who shop at food co-ops, there's nothing to worry about. These small grocers obtain their meat and produce from a handful of trusted, local farmers.

Baby boomers are aging rapidly. Around 10,000 Americans celebrate their 65th birthday every day. 

Unfortunately for these seniors, the government health care to which they're entitled may put their lives at risk. That's thanks to a new proposal from the Department of Health and Human Services that would impose price controls on certain medicines covered through Medicare.

HHS' plan could save Uncle Sam a few dollars in the short run. But its long-term side effects would be far costlier for both the government's budget and patients' health.

President Donald Trump recently promised that America "will never be a socialist country." Let's hope!

But some of his top officials at the Department of Health and Human Services apparently didn't get the memo. They’re forging ahead with a plan to impose price controls in Medicare.

Many seniors, patient advocacy groups, and health policy experts strongly oppose the proposal, which would deprive American patients of lifesaving medications. President Trump should tell his officials to stand down.

Congress is considering a bill to address problems with the patent protections afforded to American drug firms. Though well-intentioned, this bill would hamstring firms' ability to create new medicines and improve existing drugs.

If you've seen CNBC's "Shark Tank," you understand the importance of intellectual property protections. When deciding whether to invest in a young company, the business mogul "sharks" often ask whether the entrepreneur has filed for a patent. And they're impressed when the answer is "yes."

The reason? Patents are critical for innovation.

Pharmaceutical giant Biogen recently pulled the plug on its experimental Alzheimer's drug after disappointing clinical trial results.

The news shook investors. Biogen shares plummeted 32 percent, wiping $18 billion off the company's market cap. The announcement underscored how risky drug development is, especially for Alzheimer's treatments. Nearly 150 potential Alzheimer's drugs have failed during clinical trials in the past decade. 

Outside a declaration of war there is no act of Congress that would affect negatively more Americans than the House of Representative’s recently passed Equality Act now slated for the U.S. Senate, then the President for his signature.  Billed to ban discrimination against “sexual orientation” and “gender identity” it, instead, enshrines it into the 1964 Civil Rights Act potentially protecting pedophilia and pederasty under “sexual orientation.”  

President Nelson to Visit Latin America in August